CSF markers for incipient Alzheimer's disease

“Mini-mental state”

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Mild Cognitive Impairment: Clinical Characterization and Outcome

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works

Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · see citing works

tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?

Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789 · see citing works

Improved discrimination of AD patients using β-amyloid _(1-42) and tau levels in CSF

Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · see citing works

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works

Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660 · see citing works

Decreased β-Amyloid_1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · see citing works

CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 604 · see citing works

Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice

Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573 · see citing works

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

DeCarli, C. S. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00262-x · Cited by 569 · see citing works

Peptide Compositions of the Cerebrovascular and Senile Plaque Core Amyloid Deposits of Alzheimer′s Disease

Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin, Y. Y., Biemann, K., & Iqbal, K. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1112 · Cited by 510 · see citing works

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

Vanmechelen, E., Vanderstichele, H., Davidsson, P., Kerschaver, E. V., Perre, B. V. D., Sjögren, M. J. C., Andreasen, N. C., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 487 · see citing works

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01697-9 · Cited by 450 · see citing works

High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E Genotype

Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442 · see citing works

Clinical-Neuropathological Correlations in Alzheimer's Disease and Related Dementias

Galasko, D., Hansen, L. A., Katzman, R., Wiederholt, W. C., Masliah, E., Terry, R. D., Hill, L. R., Lessin, P. J., & Thal, L. J. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540210060013 · Cited by 407 · see citing works

LONG-TERM FOLLOW-UP OF PATIENTS WHO RECEIVED 10,098 SPINAL ANESTHETICS

Vandam, L. D. (1956) · JAMA · doi:10.1001/jama.1956.02970070018005 · Cited by 382 · see citing works

A4 amyloid protein deposition and the diagnosis of Alzheimer's disease

Davies, L., Wolska, B., Hilbich, C., Multhaup, G., Martins, R. N., Simms, G., Beyreuther, K. T., & Masters, C. L. (1988) · Neurology · doi:10.1212/wnl.38.11.1688 · Cited by 369 · see citing works

Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan

Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340 · see citing works

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

Otto, M., Wiltfang, J., Tumani, H., Zerr, I., Lantsch, M., Kornhuber, J., Weber, T., Kretzschmar, H. A., & Poser, S. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00215-2 · Cited by 339 · see citing works

Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease

Arai, H., Terajima, M., Miura, M., Higuchi, S., Muramatsu, T., Machida, N., Seiki, H., Takase, S., Clark, C., Lee, V. M., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380414 · Cited by 314 · see citing works

Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231

Büerger, K., Zinkowski, R. P., Teipel, S. J., Tapiola, T., Arai, H., Blennow, K., Andreasen, N., Hofmann‐Kiefer, K., DeBernardis, J. F., Kerkman, D. J., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.8.1267 · Cited by 275 · see citing works

Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

Itoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1054 · Cited by 256 · see citing works

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

Büerger, K., Teipel, S. J., Zinkowski, R. P., Blennow, K., Arai, H., Engel, R. R., Hofmann‐Kiefer, K., McCulloch, C., Ptok, U., Heun, R., et al. (2002) · Neurology · doi:10.1212/wnl.59.4.627 · Cited by 255 · see citing works

Both total and phosphorylated tau are increased in Alzheimer's disease

Sjögren, M. J. C. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.5.624 · Cited by 254 · see citing works

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias

Riemenschneider, M., Wagenpfeil, S., Vanderstichele, H., Otto, M., Wiltfang, J., Kretzschmar, H., Vanmechelen, E., Förstl, H., & Kurz, A. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001220 · Cited by 238 · see citing works

CSF levels of tau, β-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

Sjögren, M. J. C., Minthon, L., Davidsson, P., Granérus, A., Clarberg, A., Vanderstichele, H., Vanmechelen, E., Wallin, A., & Blennow, K. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070079 · Cited by 237 · see citing works

Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

Andreasen, N. C., Minthon, L., Vanmechelen, E., Vanderstichele, H., Davidsson, P., Winblad, B. G., & Blennow, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00617-5 · Cited by 236 · see citing works

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

Andreasen, N. C., Vanmechelen, E., VOORDE, A. V. D., Davidsson, P., Hesse, C., Tarvonen-Schröder, S., Räihä, I. J., Sourander, L., Winblad, B. G., & Blennow, K. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.298 · Cited by 227 · see citing works

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease

Vigo‐Pelfrey, C., Seubert, P., Barbour, R., Blomquist, C., Lee, M., Lee, D., Coria, F., Chang, L., Miller, B. L., Lieberburg, I. M., et al. (1995) · Neurology · doi:10.1212/wnl.45.4.788 · Cited by 225 · see citing works

Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease

Shoji, M., Matsubara, E., Kanai, M., Watanabe, M., Nakamura, T., Tomidokoro, Y., Shizuka, M., Wakabayashi, K., Igeta, Y., Ikeda, Y., et al. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00122-1 · Cited by 219 · see citing works

Cerebrospinal Fluid Markers for Alzheimer's Disease Evaluated after Acute Ischemic Stroke

Hesse, C., Rosengren, L., Vanmechelen, E., Vanderstichele, H., Jensen, C., Davidsson, P., & Blennow, K. (2000) · Journal of Alzheimer s Disease · doi:10.3233/jad-2000-23-402 · Cited by 215 · see citing works

Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment

Riemenschneider, M. J., Lautenschlager, N. T., Wagenpfeil, S., Diehl, J., Drzezga, A. E., & Kurz, A. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1729 · Cited by 212 · see citing works

A critical discussion of the role of neuroimaging in mild cognitive impairment*

Wolf, H., Jelić, V., Gertz, H., Nordberg, A. K., Julin, P., & Wahlund, L. (2003) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.107.s179.10.x · Cited by 211 · see citing works

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample

Andreasen, N. C., Minthon, L., Clarberg, A., Davidsson, P., Gottfries, J., Vanmechelen, E., Vanderstichele, H., Winblad, B. G., & Blennow, K. (1999) · Neurology · doi:10.1212/wnl.53.7.1488 · Cited by 210 · see citing works

Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients.

Nostrand, W. E. V., Wagner, S. L., Shankle, W. R., Farrow, J. S., Dick, M. B., Rozemüller, A. J. M., Kuiper, M. A., Wolters, E. C., Zimmerman, J. B., & Cotman, C. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2551 · Cited by 205 · see citing works

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD

Sjögren, M., Rosengren, L., Minthon, L., Davidsson, P., Blennow, K., & Wallin, A. (2000) · Neurology · doi:10.1212/wnl.54.10.1960 · Cited by 181 · see citing works

Levels of Nonphosphorylated and Phosphorylated Tau in Cerebrospinal Fluid of Alzheimer's Disease Patients

Hu, Y., He, S., Wang, X., Duan, Q., Grundke, I., Iqbal, K., & Wang, J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62554-0 · Cited by 180 · see citing works

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease

Ishiguro, K., Ohno, H., Arai, H., Yamaguchi, H., Urakami, K., Park, J., Sato, K., Kohno, H., & Imahori, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00476-0 · Cited by 175 · see citing works

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients

Kohnken, R. E., Büerger, K., Zinkowski, R. P., Miller, C., Kerkman, D. J., DeBernardis, J. F., Shen, J., Möller, H., Davies, P., & Hampel, H. J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01178-2 · Cited by 173 · see citing works

Decreased β-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

Otto, M., Esselmann, H., Schulz‐Schaeffer, W., Neumann, M., Schröter, A., Ratzka, P., Cepek, L., Zerr, I., Steinacker, P., Windl, O., et al. (2000) · Neurology · doi:10.1212/wnl.54.5.1099 · Cited by 170 · see citing works

Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration

Riemenschneider, M. J., Wagenpfeil, S., Diehl, J., Lautenschlager, N. T., Theml, T., Heldmann, B., Drzezga, A. E., Jähn, T., Förstl, H., & Kurz, A. (2002) · Neurology · doi:10.1212/wnl.58.11.1622 · Cited by 167 · see citing works

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease

Green, A. J. E., Harvey, R. J., Thompson, E. J., & Rossor, M. N. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00904-5 · Cited by 166 · see citing works

Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

Andreasen, N., Vanmechelen, E., Vanderstichele, H., Davidsson, P., & Blennow, K. (2003) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.107.s179.9.x · Cited by 160 · see citing works

Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies

Kanemaru, K., Kameda, N., & Yamanouchi, H. (2000) · Neurology · doi:10.1212/wnl.54.9.1875 · Cited by 159 · see citing works

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

Galasko, D. R., Clark, C., Chang, L., Miller, B. L., Green, R. C., Motter, R. N., & Seubert, P. A. (1997) · Neurology · doi:10.1212/wnl.48.3.632 · Cited by 153 · see citing works

Morphological and Biochemical Analyses of Amyloid Plaque Core Proteins Purified from Alzheimer Disease Brain Tissue

Roher, A. E., Palmer, K. C., Yurewicz, E. C., Ball, M. J., & Greenberg, B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09834.x · Cited by 147 · see citing works

Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms

Sjögren, M. J. C., Davidsson, P., Wallin, A., Granérus, A., Grundström, E., Askmark, H., Vanmechelen, E., & Blennow, K. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000048642 · Cited by 145 · see citing works

Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay

Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., Voorde, A., Martin, J.-J., & Cras, P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 145 · see citing works

Research Evaluation and Prospective Diagnosis of Dementia With Lewy Bodies

López, O. L., Becker, J. T., Kaufer, D., Hamilton, R. L., Sweet, R. A., Klunk, W. E., & DeKosky, S. T. (2002) · Archives of Neurology · doi:10.1001/archneur.59.1.43 · Cited by 144 · see citing works

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies

Parnetti, L., Lanari, A., Amici, S., Gallai, V., Vanmechelen, E., & Hulstaert, F. (2001) · Neurological Sciences · doi:10.1007/s100720170055 · Cited by 141 · see citing works

Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?

Kapaki, E. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.3.401 · Cited by 134 · see citing works

Low frequency of post-lumbar puncture headache in demented patients

Blennow, K., Wallin, A., & Häger, O. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb04221.x · Cited by 130 · see citing works

CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective Study

Arai, H., Ishiguro, K., Ohno, H., Moriyama, M., Itoh, N., Okamura, N., Matsui, T., Morikawa, Y.-I., Horikawa, E., Kohno, H., et al. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7501 · Cited by 123 · see citing works

Diagnostic accuracy of alzheimer’s disease: A neuropathological study

Kosunen, O., Soininen, H. S., Paljärvi, L., Heinonen, O., Talasniemi, S., & Riekkinen, P. J. (1996) · Acta Neuropathologica · doi:10.1007/s004010050412 · Cited by 119 · see citing works

The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer’s Disease, Reflecting a Common Pathophysiological Process

Sjögren, M. J. C., Davidsson, P., Gottfries, J., Vanderstichele, H., Edman, Å., Vanmechelen, E., Wallin, A., & Blennow, K. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051268 · Cited by 116 · see citing works

Combined Analysis of CSF Tau Levels and [123I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer’s Disease

Okamura, N., Arai, H., Maruyama, M., Higuchi, M., Matsui, T., Tanji, H., Seki, T., Hirai, H., Chiba, H., Itoh, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.474 · Cited by 106 · see citing works

Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy

Holmberg, B., Johnels, B., Blennow, K., & Rosengren, L. (2002) · Movement Disorders · doi:10.1002/mds.10321 · Cited by 104 · see citing works

Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231

Hampel, H. J., Büerger, K., Kohnken, R. E., Teipel, S. J., Zinkowski, R. P., Moeller, H., Rapoport, S. I., & Davies, P. (2001) · Annals of Neurology · doi:10.1002/ana.111 · Cited by 102 · see citing works

Cerebrospinal Fluid Amyloid β1–42 Levels in the Mild Cognitive Impairment Stage of Alzheimer's Disease

Maruyama, M., Arai, H., Sugita, M., Tanji, H., Higuchi, M., Okamura, N., Matsui, T., Higuchi, S., Matsushita, S., Yoshida, H., et al. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7814 · Cited by 97 · see citing works

Discriminant power of combined cerebrospinal fluid τ protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease1Preliminary parts of this study have been presented in abstract form at the 6th International Conference on Alzheimer's Disease and Related Disorders, July 18–23, 1998, Amsterdam, The Netherlands and at the 28th Annual Meeting of the Society for Neuroscience, November 7–12, 1998, Los Angeles, CA, USA.1

Hampel, H. J., Teipel, S. J., Padberg, F., Haslinger, A., Riemenschneider, M., Schwarz, M., Kötter, H. U., Scheloske, M., Buch, K., Stübner, S., et al. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01146-4 · Cited by 93 · see citing works

Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF

Kahle, P. J., Jakowec, M. W., Teipel, S. J., Hampel, H. J., Petzinger, G. M., Monte, D. A. D., Silverberg, G. D., Möller, H. ‐., Yesavage, J. A., Tinklenberg, J. R., et al. (2000) · Neurology · doi:10.1212/wnl.54.7.1498 · Cited by 93 · see citing works

Differentiation of Geriatric Major Depression From Alzheimer’s Disease With CSF Tau Protein Phosphorylated at Threonine 231

Büerger, K., Zinkowski, R. P., Teipel, S. J., Arai, H., DeBernardis, J. F., Kerkman, D. J., McCulloch, C., Padberg, F., Faltraco, F., Goernitz, A., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.376 · Cited by 92 · see citing works

Cerebrospinal protein tau is elevated in early Alzheimer's disease

Riemenschneider, M. J., Buch, K., Schmolke, M., Kurz, A., & Guder, W. G. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12810-x · Cited by 90 · see citing works

Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF

Averback, P. (2000) · Neurology · doi:10.1212/wnl.55.7.1068 · Cited by 88 · see citing works

Tau Protein in Cerebrospinal Fluid Is Significantly Increased at the Earliest Clinical Stage of Alzheimer Disease

Kurz, A., Riemenschneider, M., Buch, K., Willoch, F., Bartenstein, P., Müller, U., & Guder, W. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199812000-00020 · Cited by 85 · see citing works

Concentrations of amyloid β protein in cerebrospinal fluid of patients with alzheimer's disease

van Gool, W. A., Walstra, G. J. M., Bolhuis, P. A., Kuiper, M. A., & Wolters, E. C. (1995) · Annals of Neurology · doi:10.1002/ana.410370221 · Cited by 82 · see citing works

CSF tau protein andβ‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population

Kapaki, E., Paraskevas, G. P., Zalonis, I., & Zournas, C. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00562.x · Cited by 76 · see citing works

Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group

Shoji, M., Matsubara, E., Murakami, T., Manabe, Y., Abe, K., Kanai, M., Ikeda, M., Tomidokoro, Y., Shizuka, M., Watanabe, M., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00309-8 · Cited by 74 · see citing works

Increased cerebrospinal fluid cAMP levels in Alzheimer's disease

Martı́nez, M., Fernández, E., Frank, A., Guaza, C., la Fuente, M. D., & Hernánz, Á. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01981-2 · Cited by 73 · see citing works

Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment

de Leon, M. J., Segal, S., Tarshish, C. Y., DeSanti, S., Zinkowski, R. P., Mehta, P. D., Convit, A. J., Caraos, C., Rusinek, H., Tsui, W., et al. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01038-8 · Cited by 70 · see citing works

Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF

Vanderstichele, H., Blennow, K., D'Heuvaert, N., Buyse, M.-A., Wallin, A., Andreasen, N. C., Seubert, P. A., VOORDE, A. V. D., & Vanmechelen, E. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_110 · Cited by 70 · see citing works

Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease.

Schönknecht, P., Pantel, J., Hunt, A. M., Volkmann, M., Buerger, K., Hampel, H., & Schröder, J. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01481-7 · Cited by 68 · see citing works

Primary Degenerative Mild Cognitive Impairment: Study Population, Clinical, Brain Imaging and Biochemical Findings

Lautenschlager, N. T., Riemenschneider, M., Drzezga, A. E., & Kurz, A. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051284 · Cited by 66 · see citing works

Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls

Buch, K., Padberg, F., Nolde, T., Teipel, S. J., Stübner, S., Haslinger, A., Schwarz, M., Sunderland, T., Arai, H., Rapoport, S. I., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00845-9 · Cited by 65 · see citing works

Diagnostic accuracy of Alzheimer’s disease: A clinicopathological study

Jellinger, K. A. (1996) · Acta Neuropathologica · doi:10.1007/s004010050418 · Cited by 65 · see citing works

CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease

Tapiola, T., Lehtovirta, M., Ramberg, J., Helisalmi, S., Linnaranta, K., Riekkinen, P., & Soininen, H. S. (1998) · Neurology · doi:10.1212/wnl.50.1.169 · Cited by 63 · see citing works

Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker of Alzheimer's disease and related disorders: Multicenter study in Japan

Nishimura, T., Takeda, M., NAKAMURA, Y., et al. (1998) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.1998.20.3.485673 · Cited by 57 · see citing works

Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease.

Munroe, W. A., Southwick, P. C., Chang, L. J., Scharre, D. W., Echols, C. L., Fu, P. C., Whaley, J. M., & Wolfert, R. (1995) · PubMed · Cited by 55 · see citing works

Low cerebrospinal-fluid concentrations of soluble amyloid $beta;-protein precursor in hereditary Alzheimer's disease

Farlow, M. R. (1992) · The Lancet · doi:10.1016/0140-6736(92)91771-y · Cited by 55 · see citing works

No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia

Arai, H., Satoh‐Nakagawa, T., Higuchi, M., Morikawa, Y.-I., Miura, M., Kawakami, H., Seki, H., Takase, S., & Sasaki, H. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00781-2 · Cited by 52 · see citing works

Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics.

Morikawa, Y., Arai, H., Matsushita, S., Kato, M., Higuchi, S., Miura, M., Kawakami, H., Higuchi, M., Okamura, N., Tashiro, M., et al. (1999) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04156.x · Cited by 49 · see citing works

Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer’s disease patients

Rösler, N., Wichart, I., & Jellinger, K. A. (2001) · Journal of Neural Transmission · doi:10.1007/s007020170091 · Cited by 46 · see citing works

CSF markers related to pathogenetic mechanisms in Alzheimer's disease

Mulder, C., Schoonenboom, S. N. M., Wahlund, L., et al. (2002) · Journal of Neural Transmission · doi:10.1007/s00702-002-0763-y · Cited by 38 · see citing works

Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease.

Rösler, N., Wichart, I., & Jellinger, K. A. (1996) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.60.2.237-a · Cited by 37 · see citing works

One-Carbon Metabolism and Other Biochemical Correlates of Cognitive Impairment as Visualized by Principal Component Analysis

Gottfries, J., Blennow, K., Lehmann, M., Regland, B., & Gottfries, C. G. (2001) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198870101400302 · Cited by 36 · see citing works

Untitled work

Price (1999) · doi:10.1002/1531-8249(199903)45:3

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works

The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · see citing works

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria

Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · see citing works

Alzheimer’s disease

Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134 · see citing works

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176 · see citing works

Biomarkers for Alzheimer's disease: current status and prospects for the future

Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000 · see citing works

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · see citing works

Brain Imaging in Alzheimer Disease

Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875 · see citing works

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease

Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835 · see citing works

Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography

Mielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621 · see citing works

Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis

Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., et al. (2017) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2017.06.2266 · Cited by 585 · see citing works

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease

Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586 · see citing works

The mental wealth of nations

Beddington, J., Cooper, C. L., Field, J., Goswami, U., Huppert, F. A., Jenkins, R., Jones, H. S., Kirkwood, T. B. L., Sahakian, B. J., & Thomas, S. M. (2008) · Nature · doi:10.1038/4551057a · Cited by 554 · see citing works

Amyloid biomarkers in Alzheimer's disease

Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · see citing works

Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease: A Comparative Cerebrospinal Fluid Study

Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434 · see citing works

Total and phosphorylated tau protein as biological markers of Alzheimer’s disease

Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389 · see citing works

Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382 · see citing works

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Milà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01925-w · Cited by 353 · see citing works

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., Parnetti, L., Perret‐Liaudet, A., Shaw, L. M., Teunissen, C., et al. (2012) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2011.07.004 · Cited by 358 · see citing works

Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau

Hohman, T. J., Dumitrescu, L., Barnes, L. L., Thambisetty, M., Beecham, G., Kunkle, B., Gifford, K. A., Bush, W. S., Chibnik, L. B., Mukherjee, S., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0821 · Cited by 340 · see citing works

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease

Mattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz2387 · Cited by 359 · see citing works

Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study

Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Knopman, D. S., Lowe, V., Vemuri, P., Mielke, M. M., Roberts, R. O., Machulda, M. M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30077-7 · Cited by 333 · see citing works

Decreased cerebrospinal fluid Aβ ₄₂ correlates with brain atrophy in cognitively normal elderly

Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327 · see citing works

A data-driven model of biomarker changes in sporadic Alzheimer’s disease

Young, A. L., Oxtoby, N. P., Daga, P., Cash, D. M., Fox, N. C., Ourselin, S., Schott, J. M., & Alexander, D. C. (2014) · Brain · doi:10.1093/brain/awu176 · Cited by 308 · see citing works

Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel, R., Du, Y., Farlow, M., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001473 · Cited by 287 · see citing works

Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid

Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278 · see citing works

Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape

Hampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283 · see citing works

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease

Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266 · see citing works

High‐molecular‐weight β‐amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

Fukumoto, H., Tokuda, T., Kasai, T., Ishigami, N., Hidaka, H., Kondo, M., Allsop, D., & Nakagawa, M. (2010) · The FASEB Journal · doi:10.1096/fj.09-150359 · Cited by 264 · see citing works

Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease

Dean, D. C., Hurley, S. A., Kecskemeti, S. R., O’Grady, J. P., Canda, C., Davenport-Sis, N. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Asthana, S., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3232 · Cited by 252 · see citing works

Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease

Kester, M. I., Teunissen, C. E., Crimmins, D. L., Herries, E. M., Ladenson, J. H., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1867 · Cited by 246 · see citing works

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

Mattsson, N., Insel, P. S., Donohue, M., Landau, S., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Weiner, M. W. (2015) · Brain · doi:10.1093/brain/awu367 · Cited by 237 · see citing works

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

Zetterberg, H. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.90 · Cited by 234 · see citing works

The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease

Hirsch-Reinshagen, V., Maia, L. F., Burgess, B. L., Blain, J.-F., Naus, K. E., McIsaac, S. A., Parkinson, P. F., Chan, J. Y., Tansley, G. H., Hayden, M. R., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508781200 · Cited by 233 · see citing works

Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease

Schupf, N., Tang, M. X., Fukuyama, H., Manly, J., Andrews, H., Mehta, P., Ravetch, J., & Mayeux, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805902105 · Cited by 225 · see citing works

CSF biomarkers in frontotemporal lobar degeneration with known pathology

Bian, H., Van Swieten, J. C., Leight, S., Massimo, L., Wood, E., Forman, M., Moore, P., de Koning, I., Clark, C. M., Rosso, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000311445.21321.fc · Cited by 216 · see citing works

Fluid Biomarkers in Alzheimer Disease

Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208 · see citing works

Cerebrospinal fluid biomarkers in Parkinson disease

Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., & Calabresi, P. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.10 · Cited by 209 · see citing works

Altered Proteins in the Aging Brain

Elobeid, A., Libard, S., Leino, M., Popova, S. N., & Alafuzoff, I. (2016) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1093/jnen/nlw002 · Cited by 202 · see citing works

Levels of β-Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment

Zhong, Z., Ewers, M., Teipel, S., Bürger, K., Wallin, A., Blennow, K., He, P., McAllister, C., Hampel, H., & Shen, Y. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.718 · Cited by 206 · see citing works

Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease

Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Shaw, L. M., Trojanowski, J. Q., Aisen, P. S., Weiner, M., Petersen, R. C., Jack, C. R., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21953 · Cited by 195 · see citing works

Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints

van Harten, A. C., Visser, P. J., Pijnenburg, Y. A. L., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2012.08.004 · Cited by 197 · see citing works

18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease

Mattsson, N., Schöll, M., Strandberg, O., Smith, R., Palmqvist, S., Insel, P. S., Hägerström, D., Ohlsson, T., Zetterberg, H., Jögi, J., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707809 · Cited by 177 · see citing works

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease

Ashton, N. J., Benedet, A. L., Pascoal, T. A., Karikari, T. K., Lantero-Rodriguez, J., Brum, W. S., Mathotaarachchi, S., Therriault, J., Savard, M., Chamoun, M., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.103836 · Cited by 184 · see citing works

Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers

Kester, M. I., Goos, J. D. C., Teunissen, C. E., Benedictus, M. R., Bouwman, F. H., Wattjes, M. P., Barkhof, F., Scheltens, P., & van der Flier, W. M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.754 · Cited by 161 · see citing works

An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform

Li, D., & Mielke, M. M. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00164-5 · Cited by 147 · see citing works

Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention

Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149 · see citing works

CSF biomarkers for mild cognitive impairment

Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151 · see citing works

Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort

Kester, M. I., Teunissen, C. E., Sutphen, C., Herries, E. M., Ladenson, J. H., Xiong, C., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., et al. (2015) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-015-0142-1 · Cited by 146 · see citing works

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

Herukka, S.-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2016.09.009 · Cited by 141 · see citing works

Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies

Barthélemy, N. R., Gabelle, A., Hirtz, C., Fenaille, F., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Junot, C., Becher, F., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150962 · Cited by 139 · see citing works

The implications of different approaches to define AT(N) in Alzheimer disease

Mattsson-Carlgren, N., Leuzy, A., Janelidze, S., Palmqvist, S., Stomrud, E., Strandberg, O., Smith, R., & Hansson, O. (2020) · Neurology · doi:10.1212/wnl.0000000000009485 · Cited by 114 · see citing works

<i>APOE</i> ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42

Prince, J. A., Zetterberg, H., Andreasen, N., Marcusson, J., & Blennow, K. (2004) · Neurology · doi:10.1212/01.wnl.0000128088.08695.05 · Cited by 128 · see citing works

Seed‐competent high‐molecular‐weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients

Takeda, S., Commins, C., DeVos, S. L., Nobuhara, C. K., Wegmann, S., Roe, A. D., Costantino, I., Fan, Z., Nicholls, S. B., Sherman, A. E., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24716 · Cited by 113 · see citing works

Increased CSF-BACE 1 activity is associated with ApoE-ε4 genotype in subjects with mild cognitive impairment and Alzheimer's disease

Ewers, M., Zhong, Z., Bürger, K., Wallin, A., Blennow, K., Teipel, S. J., Shen, Y., & Hampel, H. (2008) · Brain · doi:10.1093/brain/awn034 · Cited by 119 · see citing works

Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls

Chou, Y.-Y., Leporé, N., Avedissian, C., Madsen, S. K., Parikshak, N., Hua, X., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Toga, A. W., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.02.015 · Cited by 117 · see citing works

The keystone of Alzheimer pathogenesis might be sought in Aβ physiology

Puzzo, D., Gulisano, W., Arancio, O., & Palmeri, A. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.039 · Cited by 116 · see citing works

A novel, ultrasensitive assay for tau: potential for assessing traumatic brain injury in tissues and biofluids.

Rubenstein, R., Chang, B., Davies, P., Wagner, A. K., Robertson, C. S., & Wang, K. K. W. (2015) · Journal of Neurotrauma · doi:10.1089/neu.2014.3548 · Cited by 116 · see citing works

Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms

Nilselid, A.-M., Davidsson, P., Nägga, K., Andreasen, N., Fredman, P., & Blennow, K. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.005 · Cited by 104 · see citing works

Imaging plus X: multimodal models of neurodegenerative disease

Oxtoby, N. P., & Alexander, D. C. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000460 · Cited by 105 · see citing works

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease

Schindler, S. E., Li, Y., Todd, K. W., Herries, E. M., Henson, R. L., Gray, J. D., Wang, G., Graham, D. L., Shaw, L. M., Trojanowski, J. Q., et al. (2019) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2018.12.019 · Cited by 101 · see citing works

Sex differences in the genetic predictors of Alzheimer’s pathology

Dumitrescu, L., Barnes, L. L., Thambisetty, M., Beecham, G., Kunkle, B., Bush, W. S., Gifford, K. A., Chibnik, L. B., Mukherjee, S., De Jager, P. L., et al. (2019) · Brain · doi:10.1093/brain/awz206 · Cited by 93 · see citing works

The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease

Hadjichrysanthou, C., Evans, S., Bajaj, S., Siakallis, L. C., McRae-McKee, K., de Wolf, F., Anderson, R. M., & Initiative, T. A. D. N. (2020) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-020-00636-z · Cited by 86 · see citing works

Extreme cerebrospinal fluid amyloid β levels identify family with late‐onset Alzheimer's disease presenilin 1 mutation

Kauwe, J. S. K., Jacquart, S., Chakraverty, S., Wang, J., Mayo, K., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Goate, A. M. (2007) · Annals of Neurology · doi:10.1002/ana.21099 · Cited by 84 · see citing works

Advances in Alzheimer's disease research over the past two decades

Jack, C. R. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00298-8 · Cited by 83 · see citing works

Synaptic vesicle protein 2A as a potential biomarker in synaptopathies

Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.001 · Cited by 77 · see citing works

Apolipoprotein E Genotype Affects Size of ApoE Complexes in Cerebrospinal Fluid

Heinsinger, N. M., Gachechiladze, M. A., & Rebeck, G. W. (2016) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1093/jnen/nlw067 · Cited by 74 · see citing works

The neuroinflammatory role of microglia in Alzheimer's disease and their associated therapeutic targets

AmeliMojarad, M., & AmeliMojarad, M. (2024) · CNS Neuroscience &amp; Therapeutics · doi:10.1111/cns.14856 · Cited by 73 · see citing works

Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease

Skogseth, R., Mulugeta, E., Ballard, C., Rongve, A., Nore, S., Alves, G., & Aarsland, D. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000137671 · Cited by 71 · see citing works

The innate immune system in Alzheimer's disease

Boutajangout, A., & Wisniewski, T. (2013) · International Journal of Cell Biology · doi:10.1155/2013/576383 · Cited by 69 · see citing works

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease

Blennow, K., & Zetterberg, H. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.012 · Cited by 69 · see citing works

Arginine vasopressin in cerebrospinal fluid is a marker of sociality in nonhuman primates

Parker, K. J., Garner, J. P., Oztan, O., Tarara, E. R., Li, J., Sclafani, V., Del Rosso, L. A., Chun, K., Berquist, S. W., Chez, M. G., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam9100 · Cited by 64 · see citing works

Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates

Russell, C. L., Mitra, V., Hansson, K., Blennow, K., Gobom, J., Zetterberg, H., Hiltunen, M., Ward, M., & Pike, I. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160633 · Cited by 52 · see citing works

Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer’s disease

Ewers, M., Cheng, X., Zhong, Z., Nural, H. F., Walsh, C., Meindl, T., Teipel, S. J., Buerger, K., He, P., Shen, Y., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-091153 · Cited by 58 · see citing works

Cerebrospinal Fluid Tau Cleaved by Caspase-6 Reflects Brain Levels and Cognition in Aging and Alzheimer Disease

Ramcharitar, J., Albrecht, S., Afonso, V. M., Kaushal, V., Bennett, D. A., & LeBlanc, A. C. (2013) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1097/nen.0b013e3182a0a39f · Cited by 47 · see citing works

CSF Aβ42, Tau and Phosphorylated Tau Correlate with Medial Temporal Lobe Atrophy

Herukka, S.-K., Pennanen, C., Soininen, H., & Pirttilä, T. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-14105 · Cited by 47 · see citing works

Magnetic resonance and PET studies in the early diagnosis of Alzheimer’s disease

Mosconi, L., De Santi, S., Rusinek, H., Convit, A., & de Leon, M. J. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.5.831 · Cited by 46 · see citing works

Diagnostic biomarkers in Alzheimer’s disease

Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2021.100041 · Cited by 42 · see citing works

Retinal examination for the diagnosis of Alzheimer's disease

Kayabasi, U. (2014) · International Journal of Ophthalmic &amp; Pathology · doi:10.4172/2324-8599.1000145 · Cited by 34 · see citing works

Analysis of Human Tau in Cerebrospinal Fluid

Hanisch, K., Soininen, H., Alafuzoff, I., & Hoffmann, R. (2010) · Journal of Proteome Research · doi:10.1021/pr901002t · Cited by 17 · see citing works

Molecular forms of hippocampal acetylcholinesterase and their changes following septal lesions in the rat.

Bajgar, J., & Herink, J. (1991) · PubMed · Cited by 1 · see citing works

The Effects of Exercise-induced Fatigue on Acetylcholinesterase Expression and Activity at Rat Neuromuscular Junctions

Wen, G., Wang, H., Chen, D., Wu, X., Tong, J., Li, C.-Q., De-liang, L., Wei-Jun, C., Li, Z., & Luo, X. (2009) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.09019 · Cited by 15 · see citing works

Acetylcholinesterase 정성검사에 용혈 검체가 미치는 영향

문지은, 오. (2015)

Quaternary Heteroarenium Salts as the Competitive Inhibitors of the Brain Acetylcholinesterase

Kuča, K., Cabal, J., Patočka, J., et al. (2004) · Letters in Drug Design & Discovery · doi:10.2174/1570180043485509 · Cited by 15 · see citing works

Myrtenal inhibits acetylcholinesterase, a known Alzheimer target

Kaufmann, D., Dogra, A. K., & Wink, M. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01344.x · Cited by 80 · see citing works